Physician profile
Alexandra E Akra
NPI 1245667559
$1,330.08
in general payments reported to CMS, 2019-2025
20 companies · $716 in 2025
The $716 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $614 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $162.20 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $158.74 | 2024-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $152.20 | 2024-2025 | Veozah |
| Novo Nordisk INC | $147.49 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Eisai INC. | $125.00 | 2025 | |
| Inspire Medical Systems, INC. | $121.52 | 2025 | Inspire |
| Lilly USA, LLC | $112.85 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Shield Therapeutics INC | $74.28 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.02 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $32.87 | 2024-2025 | Rexulti |
| Amgen INC. | $30.86 | 2024 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $29.79 | 2024 | Gemtesa |
| Abbott Laboratories | $24.57 | 2025 | Freestyle Libre 3 |
| Globus Medical, INC. | $21.23 | 2025 | Senza |
| Dynavax Technologies Corporation | $20.02 | 2024 | Heplisav-B |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.50 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $18.24 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.11 | 2024 | Xarelto |
| Lundbeck LLC | $13.83 | 2025 | Rexulti |
| Ibsa Pharma INC. | $13.76 | 2025 | Tirosint, Flector, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Akra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.